AstraZeneca (AZN) Resumen de Acciones
AstraZeneca PLC, empresa biofarmacéutica, centra su actividad en el descubrimiento, desarrollo, fabricación y comercialización de medicamentos de venta con receta. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 3/6 |
| Dividendos | 3/6 |
Recompensas
Análisis de riesgos
AZN Community Fair Values
Create NarrativeSee what 299 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de AstraZeneca PLC
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | UK£125.94 |
| Máximo en las últimas 52 semanas | UK£157.32 |
| Mínimo de 52 semanas | UK£98.92 |
| Beta | 0.22 |
| Cambio en 1 mes | -6.52% |
| Variación en 3 meses | -16.70% |
| Cambio de 1 año | 22.34% |
| Variación en 3 años | 16.94% |
| Variación en 5 años | 48.51% |
| Variación desde la OPV | 1,796.69% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.
Actualización de narrativa • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.Recent updates
Actualización de narrativa • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.Actualización de narrativa • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.Artículo de análisis • Jun 19
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
Actualización de narrativa • Jun 18
AZN: New Approvals And AI Use Will Support Future Repricing
The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.Actualización de narrativa • Jun 03
AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing
Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.Actualización de narrativa • Apr 29
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.Actualización de narrativa • Apr 15
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.Actualización de narrativa • Apr 01
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.Actualización de narrativa • Mar 18
AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.Actualización de narrativa • Mar 03
AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.Actualización de narrativa • Feb 17
AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.Actualización de narrativa • Feb 03
AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook
Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.Actualización de narrativa • Jan 20
AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating
Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.Actualización de narrativa • Jan 06
AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns
AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.Actualización de narrativa • Dec 14
AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.Actualización de narrativa • Nov 28
AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects
AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.Actualización de narrativa • Nov 14
AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes
AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.Artículo de análisis • Nov 13
AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest
AstraZeneca PLC's ( LON:AZN ) strong earnings report was rewarded with a positive stock price move. We have done some...Actualización de narrativa • Oct 31
AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance
AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.Rentabilidad de los accionistas
| AZN | GB Pharmaceuticals | Mercado GB | |
|---|---|---|---|
| 7D | -1.9% | -1.4% | 1.0% |
| 1Y | 22.3% | 22.9% | 17.2% |
Rentabilidad vs. Industria: AZN igualó a la industria UK Pharmaceuticals, que obtuvo un rendimiento del 22.9% el año pasado.
Rentabilidad vs. Mercado: AZN superó al mercado UK, que obtuvo un rendimiento del 17.2% el año pasado.
Volatilidad de los precios
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.7% |
Precio estable de las acciones: AZN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado UK.
Volatilidad a lo largo del tiempo: La volatilidad semanal de AZN (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, empresa biofarmacéutica, se centra en el descubrimiento, desarrollo, fabricación y comercialización de medicamentos de prescripción. La empresa ofrece Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules y Symbicort pMDI. También suministra Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium y otros medicamentos.
Resumen de fundamentos de AstraZeneca PLC
| Estadísticas fundamentales de AZN | |
|---|---|
| Capitalización bursátil | UK£195.34b |
| Beneficios(TTM) | UK£7.72b |
| Ingresos (TTM) | UK£44.91b |
25.3x
Ratio precio-beneficio (PE)4.3x
Ratio precio-ventas (PS)¿Está AZN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AZN | |
|---|---|
| Ingresos | US$60.44b |
| Coste de los ingresos | US$11.18b |
| Beneficio bruto | US$49.26b |
| Otros gastos | US$38.87b |
| Beneficios | US$10.39b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 27, 2026
| Beneficios por acción (BPA) | 6.70 |
| Margen bruto | 81.51% |
| Margen de beneficio neto | 17.19% |
| Ratio deuda/patrimonio | 67.8% |
¿Cómo se ha desempeñado AZN a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.8%
Rentabilidad actual por dividendo48%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/17 00:01 |
| Precio de las acciones al final del día | 2026/07/17 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AstraZeneca PLC está cubierta por 56 analistas. 24 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |